These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20554570)

  • 21. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of vancomycin minimum inhibitory concentration on the outcome of methicillin-susceptible Staphylococcus aureus left-sided infective endocarditis treated with antistaphylococcal β-lactam antibiotics: a prospective cohort study by the International Collaboration on Endocarditis.
    Pericàs JM; Messina JA; Garcia-de-la-Mària C; Park L; Sharma-Kuinkel BK; Marco F; Wray D; Kanafani ZA; Carugati M; Durante-Mangoni E; Tattevin P; Chu VH; Moreno A; Fowler VG; Miró JM;
    Clin Microbiol Infect; 2017 Aug; 23(8):544-549. PubMed ID: 28159672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of methicillin-resistant Staphylococcus aureus infections with a minimal inhibitory concentration of 2 μg/mL to vancomycin: old (trimethoprim/sulfamethoxazole) versus new (daptomycin or linezolid) agents.
    Campbell ML; Marchaim D; Pogue JM; Sunkara B; Bheemreddy S; Bathina P; Pulluru H; Chugh N; Wilson MN; Moshos J; Ku K; Hayakawa K; Martin ET; Lephart PR; Rybak MJ; Kaye KS
    Ann Pharmacother; 2012 Dec; 46(12):1587-97. PubMed ID: 23212935
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus.
    Fowler VG; Boucher HW; Corey GR; Abrutyn E; Karchmer AW; Rupp ME; Levine DP; Chambers HF; Tally FP; Vigliani GA; Cabell CH; Link AS; DeMeyer I; Filler SG; Zervos M; Cook P; Parsonnet J; Bernstein JM; Price CS; Forrest GN; Fätkenheuer G; Gareca M; Rehm SJ; Brodt HR; Tice A; Cosgrove SE;
    N Engl J Med; 2006 Aug; 355(7):653-65. PubMed ID: 16914701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparing probability of target attainment against Staphylococcus aureus for ceftaroline fosamil, vancomycin, daptomycin, linezolid, and ceftriaxone in complicated skin and soft tissue infection using pharmacokinetic/pharmacodynamic models.
    Cristinacce A; Wright JG; Macpherson M; Iaconis J; Das S
    Diagn Microbiol Infect Dis; 2021 Apr; 99(4):115292. PubMed ID: 33360809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Susceptibility relationship between vancomycin and daptomycin in Staphylococcus aureus: facts and assumptions.
    Moise PA; North D; Steenbergen JN; Sakoulas G
    Lancet Infect Dis; 2009 Oct; 9(10):617-24. PubMed ID: 19778764
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia.
    Kullar R; Davis SL; Kaye KS; Levine DP; Pogue JM; Rybak MJ
    Pharmacotherapy; 2013 Jan; 33(1):3-10. PubMed ID: 23307539
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies.
    Keel RA; Sutherland CA; Aslanzadeh J; Nicolau DP; Kuti JL
    Diagn Microbiol Infect Dis; 2010 Nov; 68(3):326-9. PubMed ID: 20955917
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of decreased susceptibility to daptomycin and vancomycin in a Staphylococcus aureus strain during prolonged therapy.
    Mariani PG; Sader HS; Jones RN
    J Antimicrob Chemother; 2006 Aug; 58(2):481-3. PubMed ID: 16847029
    [No Abstract]   [Full Text] [Related]  

  • 30. Daptomycin non-susceptible Staphylococcus aureus at a US medical centre.
    Velazquez A; DeRyke CA; Goering R; Hoover V; Wallace MR
    Clin Microbiol Infect; 2013 Dec; 19(12):1169-72. PubMed ID: 23480569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Activities of antistaphylococcal antibiotics towards the extracellular and intraphagocytic forms of Staphylococcus aureus isolates from a patient with persistent bacteraemia and endocarditis.
    Lemaire S; Kosowska-Shick K; Julian K; Tulkens PM; Van Bambeke F; Appelbaum PC
    Clin Microbiol Infect; 2008 Aug; 14(8):766-77. PubMed ID: 18727801
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence.
    Stefani S; Campanile F; Santagati M; Mezzatesta ML; Cafiso V; Pacini G
    Int J Antimicrob Agents; 2015 Sep; 46(3):278-89. PubMed ID: 26143590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of invitrosynergy of daptomycin or vancomycin plus ceftaroline for daptomycin non-susceptible Staphylococcus aureus.
    Hutton MA; Sundaram A; Perri MB; Zervos MJ; Herc ES
    Diagn Microbiol Infect Dis; 2020 Nov; 98(3):115126. PubMed ID: 32861155
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory activities of 11 antimicrobial agents and bactericidal activities of vancomycin and daptomycin against invasive methicillin-resistant Staphylococcus aureus isolates obtained from 1999 through 2006.
    Holmes RL; Jorgensen JH
    Antimicrob Agents Chemother; 2008 Feb; 52(2):757-60. PubMed ID: 18039923
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Vancomycin-resistant enterococcal bacteraemia and daptomycin: are higher doses necessary?
    King EA; McCoy D; Desai S; Nyirenda T; Bicking K
    J Antimicrob Chemother; 2011 Sep; 66(9):2112-8. PubMed ID: 21697178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emergence of a small colony variant of vancomycin-intermediate Staphylococcus aureus in a patient with septic arthritis during long-term treatment with daptomycin.
    Lin YT; Tsai JC; Yamamoto T; Chen HJ; Hung WC; Hsueh PR; Teng LJ
    J Antimicrob Chemother; 2016 Jul; 71(7):1807-14. PubMed ID: 26968883
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bacteremia and infective endocarditis caused by a non-daptomycin-susceptible, vancomycin-intermediate, and methicillin-resistant Staphylococcus aureus strain in Taiwan.
    Huang YT; Hsiao CH; Liao CH; Lee CW; Hsueh PR
    J Clin Microbiol; 2008 Mar; 46(3):1132-6. PubMed ID: 18199793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
    Patel N; Lubanski P; Ferro S; Bonafede M; Harrington S; Evans A; Stellrecht K; Lodise TP
    Antimicrob Agents Chemother; 2009 Dec; 53(12):5141-4. PubMed ID: 19805558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Community-phenotype-methicillin-resistant Staphylococcus aureus infections: a retrospective chart review of outcomes after treatment with daptomycin.
    Katz DE; Martone WJ
    Clin Ther; 2007 Nov; 29(11):2440-7. PubMed ID: 18158084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Duration of prior vancomycin therapy and subsequent daptomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteremia.
    Culshaw D; Lamp KC; Yoon MJ; Lodise TP
    Diagn Microbiol Infect Dis; 2015 Oct; 83(2):193-7. PubMed ID: 26184127
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.